Stock Analiz

TScan Therapeutics, Inc. TCRX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.16Market cap $10M
Open the interactive analysis →

TScan Therapeutics, Inc. (TCRX) is a healthcare company listed in the US with a market value of about $10M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$115M, a net margin of -2219.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 57% a year, a 5-year average ROIC of -33%.

About TScan Therapeutics

TScan Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $1M in 2020 to $10M in 2025, growth of about 56.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 440% over three years (dilution for shareholders). It spends 1106% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.0
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1094.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)266.7%
Revenue growth (5 yrs, per year)56.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1435.4%
ROIC (5-yr avg.)-32.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$5M$10M$3M$21M$14M$10M$1M
Net income-$115M-$130M-$127M-$89M-$66M-$49M-$26M
Free cash flow-$112M-$140M-$115M-$65M-$71M-$59M-$7M
EPS (diluted)$-0.89$-2.00$-2.28$-2.72$-5.50$-8.34$-57.04
Net margin-2219.2%-1256.8%-4527.7%-423.9%-489.3%-479.5%-2408.0%
ROIC—-49.4%-31.5%-30.3%-28.4%-23.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $1.00, 523% above the current price; targets range from $1.00 to $1.00; the consensus rating is “Hold”; expected EPS is $-0.83 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does TScan Therapeutics pay a dividend?

Not currently.

Is TScan Therapeutics a good stock to buy?

We do not give buy or sell advice. TScan Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.